CA 19-9

CA 19-9 is a blood test that measures a tumor-associated carbohydrate antigen called sialyl-Lewis a. It is produced by cells in the pancreas, bile ducts, and some other parts of the digestive system, and can be released into the bloodstream when these tissues are inflamed or when a tumor is present.

It is most commonly used in the care of people with pancreatic or biliary cancers, together with imaging and clinical evaluation. CA 19-9 is not a general cancer screening test, and it can be low even in some people with cancer because a small portion of the population does not make this antigen at all.

Your clinician may order CA 19-9 to help monitor known pancreatic or biliary cancers, to assess how treatment is working, and to watch for possible recurrence after treatment. It can also be checked when there is concern for problems in the pancreas or bile ducts, alongside other tests and imaging.

CA 19-9 levels can rise with noncancer conditions such as bile duct blockage, pancreatitis, or liver disease, so the result is interpreted in context. Because elevations are not specific and some people do not produce CA 19-9, the test is not used alone to diagnose or screen for cancer in the general population.

Results are best understood by looking at trends over time and by combining them with your symptoms, examination, other blood tests, and imaging. A falling value during treatment may suggest response, while a rising value may signal tumor activity or a noncancer cause such as bile duct blockage.

If your result is higher than expected, your clinician may repeat the test, address possible reversible causes, or order imaging. If your result is low or undetectable, this does not exclude cancer, especially in individuals who do not produce CA 19-9. Discuss your results with your care team to decide next steps.